Search

everythingexperts & clinicslearnresearchcommunity

for

Search:↓

Managing estradiol levels while using finasteride. Treatments discussed include Minoxidil, finasteride, and RU58841.

The user experienced significant hair regrowth using a treatment regimen including finasteride, oral and topical minoxidil, RU58841, red light therapy, microneedling, and various supplements. They switched from dutasteride to finasteride due to side effects and reported improved results and well-being.

The conversation discusses the comparison of Pyrilutamide Phase II US trial results with 1 mg finasteride for hair loss treatment. It mentions that the total hair count increase in the US trial was not as good as the China trial.

The user is experiencing severe hair thinning and is using multiple treatments including topical finasteride, minoxidil, tretinoin, latanoprost, oral minoxidil, dutasteride, saw palmetto, and derma wounding. They are considering adding RU58841 and are contemplating a hair transplant and exosomes due to frustration with current results.

User asks about Pyrilutamide release in Europe, specifically Germany, and considers importing it from China. No specific treatments mentioned.

The conversation discusses the anticipation of Chinese manufacturers producing Clascoterone 5% before its full approval in 2027. It also mentions treatments like Minoxidil, finasteride, and RU58841 for hair loss.

PP405 is anticipated as a future treatment for dormant hair follicles, but its effectiveness and safety are uncertain. Current treatments include oral minoxidil and microneedling, with some avoiding finasteride due to side effects.

The conversation discusses an interview with Dr. Tsuji about hair follicle stem cell multiplication and the financial challenges of starting human clinical trials. It also mentions the need for funding to secure a patent for a protein that promotes hair growth.

A 23-year-old is experiencing hair loss, primarily at the top middle of the head, and is considering finasteride but is hesitant due to potential side effects. Other users share their positive experiences with finasteride, suggesting it is worth trying, while also discussing the importance of researching and monitoring for any side effects.

Pyrilutamide, a potential hair loss treatment that has recently been released for sale, and is thought to have similar efficacy to Dutasteride without side effects. It was discussed in terms of its effectiveness compared to Finasteride, its use by females, and whether it can be safely mixed with RU58841.

Breezula's phase 3 results are expected soon, with discussions on the effectiveness of androgen receptor antagonists like spironolactone and the potential of GT20029. Users express skepticism about new treatments and discuss the complexities of male pattern baldness, often relying on finasteride despite its side effects.

The user shared a 4-month update on their hair loss treatment, using 2.5 mg OM daily, 0.5 mg Dutasteride three times a week, and a multivitamin with biotin. They provided progress pictures to show their results.

The conversation discusses the use of Verteporfin in treating hair loss. Specific treatments mentioned include Minoxidil, Finasteride, and RU58841.

A user had a failed hair transplant with 2800 FUE grafts at a clinic in Turkey, where finasteride was used, and the procedure was poorly executed by technicians rather than the main surgeon. The user later sought repair from a more experienced doctor, highlighting issues with large clinics that handle multiple patients daily.

A 23-year-old male is experiencing diffuse hair loss and miniaturization, possibly due to high IGE levels after using tofacitinib. He seeks advice and has not yet consulted a dermatologist.

The user received hormone test results showing normal estradiol and testosterone levels, low SHBG, and normal free androgen index. They are considering starting finasteride but are concerned due to being slightly overweight.

Alfatradiol (0.025%) is an effective and safe treatment for androgenetic alopecia in both men and women, increasing anagen hair rates with minimal side effects. Users discuss its cost-effectiveness and ease of use compared to other treatments like finasteride and RU58841, with some combining it with stemoxydine and Minoxidil.

The user experienced hair loss due to a crash diet and later developed scarring hair loss. They are now on finasteride, oral minoxidil, LDN, Zyrtec, and Oztela to reduce scalp inflammation and promote hair regrowth.

PP405's phase 2a trial results were presented, focusing on safety and pharmacokinetics, with a future meeting planned to share the full dataset. The trial includes a randomized controlled portion and an open-label extension, with no indication of phase 2B completion.

A 19-year-old female is experiencing significant hair loss, with symptoms including alternating hair colors and thinning body hair. She seeks advice on coping and potential treatments, with suggestions to consult a dermatologist and check thyroid and hormone levels.

A user humorously suggests an extreme hair loss treatment regimen involving multiple medications and therapies, including Dutasteride, Minoxidil, RU58841, and others, claiming it would prevent hair loss but with potential side effects like gynecomastia. The conversation highlights concerns about safety, side effects, and the effectiveness of such a comprehensive approach.

HMI-115, a newly discovered hair loss treatment that could potentially be effective for those with diffuse thinning and telogen effluvium. It is based on prolactin receptor antagonist signaling and has already undergone Phase I trials in women, with potential commercialization by 2027.

A female experiencing hair loss while on testosterone replacement therapy is using oral Minoxidil, Spironolactone, and finasteride, but still losing hair. Suggestions include switching to dutasteride, using topical anti-androgens, and reducing Nizoral shampoo use to prevent scalp dryness.

Clascoterone, a topical anti-androgen for hair loss, is expected to be released in late 2026 or early 2027.

A 22-year-old is planning a hair transplant for the end of 2027 and is currently using finasteride, switching to dutasteride soon, and taking oral minoxidil to stabilize hair loss. They are seeking advice on candidacy and the number of grafts needed.

The user is experiencing stage 2 hair loss and thinning, noticing more scalp visibility with short hair. They are considering diet, yoga, scalp massage, supplements, and a serum recommended by their doctor, and questioning if it's safe to stop using the serum and whether to get a blood test since hair loss isn't a family trait.

The user is treating hair loss with a regimen including Dutasteride, oral and topical Minoxidil, microneedling, and various supplements for overall health. They are considering adding tretinoin, stemoxydine/RU, DIM, Boron, and Fadogia Agretis to their routine.

The conversation discusses using topical cetirizine as a treatment for androgenetic alopecia (hair loss). Specific treatments mentioned include Minoxidil, finasteride, and RU58841.

Spironolactone, finasteride, and dutasteride are discussed for hair maintenance, with concerns about testosterone and side effects like gynecomastia. Spironolactone is noted for use in both bodybuilding and hormone therapy, with low doses considered for minimizing side effects.

The user is concerned about hair loss and is using treatments like dutasteride, microneedling, and topical finasteride, while considering adding RU58841. They are also using Minoxidil on the temples and are worried about testosterone-related hair loss.